PMID- 28089441
OWN - NLM
STAT- MEDLINE
DCOM- 20171108
LR  - 20180423
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 17
IP  - 3
DP  - 2017 Mar
TI  - Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
PG  - 159-164.e2
LID - S2152-2650(16)30953-3 [pii]
LID - 10.1016/j.clml.2016.12.001 [doi]
AB  - BACKGROUND: Cytogenetic analysis aides in risk stratification for patients with 
      multiple myeloma (MM). Although several cytogenetic aberrations have been 
      reported to be prognostic, less is known about the association between the 
      presence of monosomies and prognosis. The present study evaluated the prevalence 
      and prognostic implications of monosomies in patients with MM. MATERIALS AND 
      METHODS: Karyotypes were determined using conventional cytogenetics and 
      fluorescence in situ hybridization (FISH). The prognostic effect of monosomies 
      was evaluated by comparison with the clinical factors in MM patients with normal 
      karyotypes. RESULTS: Karyotypes were successfully determined in 167 of the 170 
      patients with MM. Of these 167 patients, 52 (31.1%) had abnormal karyotypes. 
      Univariable analyses showed that a normal karyotype, hypodiploidy, monosomies of 
      chromosomes 13 and 16, deletion or monosomy of 13q14, and loss of X detected by 
      metaphase analysis were each associated with reduced progression-free survival 
      (P < .05 for each). Univariable analyses showed that a normal karyotype, 
      hypodiploidy, monosomies of chromosomes 13 and 16, deletion or monosomy of 13q14 
      detected by metaphase analysis and FISH-determined RB1 (13q)/TP53 (17p) deletion 
      were each associated with reduced overall survival (P < .05 for each). 
      Multivariable analysis showed that hypodiploidy detected by metaphase analysis 
      was independently prognostic of shorter progression-free survival (P < .05 for 
      each) and that hypodiploidy, monosomy 16, and loss of Y chromosome and 
      FISH-determined TP53 (17p) deletion were associated with reduced overall survival 
      (P < .05 for each). CONCLUSION: In addition to known cytogenetic abnormalities, 
      such as monosomy 13, hypodiploidy, and TP53 (17p) deletion, monosomy 16 and loss 
      of the Y chromosome have adverse prognostic implications in patients with MM.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Shin, Sang-Yong
AU  - Shin SY
AD  - Department of Laboratory Medicine, Center for Diagnostic Oncology and 
      Translational Epidemiology Research Branch, Hospital and Research Institute, 
      National Cancer Center, Goyang, Korea.
FAU - Eom, Hyeon-Seok
AU  - Eom HS
AD  - Department of Hematology-Oncology, Center for Hematologic Malignancy, National 
      Cancer Center, Goyang, Korea; Department of System Cancer Science, Graduate 
      School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
FAU - Sohn, Ji Yeon
AU  - Sohn JY
AD  - Department of Laboratory Medicine, Center for Diagnostic Oncology and 
      Translational Epidemiology Research Branch, Hospital and Research Institute, 
      National Cancer Center, Goyang, Korea.
FAU - Lee, Hyewon
AU  - Lee H
AD  - Department of Hematology-Oncology, Center for Hematologic Malignancy, National 
      Cancer Center, Goyang, Korea; Hematologic Malignancy Branch, Research Institute, 
      National Cancer Center, Goyang, Korea.
FAU - Park, Boram
AU  - Park B
AD  - Biometric Research Branch, Research Institute, National Cancer Center, Goyang, 
      Korea.
FAU - Joo, Jungnam
AU  - Joo J
AD  - Biometric Research Branch, Research Institute, National Cancer Center, Goyang, 
      Korea.
FAU - Jang, Ja-Hyun
AU  - Jang JH
AD  - Green Cross Genome, Yongin, Korea.
FAU - Lee, Mi-Na
AU  - Lee MN
AD  - Green Cross Laboratories, Yongin, Korea.
FAU - Kim, Jung Kwon
AU  - Kim JK
AD  - Department of Laboratory Medicine, Center for Diagnostic Oncology and 
      Translational Epidemiology Research Branch, Hospital and Research Institute, 
      National Cancer Center, Goyang, Korea.
FAU - Kong, Sun-Young
AU  - Kong SY
AD  - Department of Laboratory Medicine, Center for Diagnostic Oncology and 
      Translational Epidemiology Research Branch, Hospital and Research Institute, 
      National Cancer Center, Goyang, Korea; Department of Hematology-Oncology, Center 
      for Hematologic Malignancy, National Cancer Center, Goyang, Korea; Department of 
      System Cancer Science, Graduate School of Cancer Science and Policy, National 
      Cancer Center, Goyang, Korea; Translational Epidemiology Research Branch, 
      Research Institute, National Cancer Center, Goyang, Korea. Electronic address: 
      ksy@ncc.re.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161226
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Deletion
MH  - Chromosome Disorders/genetics
MH  - Chromosomes, Human, Pair 13/genetics
MH  - Chromosomes, Human, Pair 16/genetics
MH  - Chromosomes, Human, Y/genetics
MH  - Cytogenetic Analysis/methods
MH  - Cytogenetics/methods
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Karyotyping/methods
MH  - Male
MH  - Middle Aged
MH  - Monosomy/*genetics
MH  - Multiple Myeloma/*genetics/*pathology
MH  - Prognosis
OTO - NOTNLM
OT  - Cytogenetics
OT  - MM
OT  - Monosomy
OT  - Prognosis
OT  - Survival
EDAT- 2017/01/17 06:00
MHDA- 2017/11/09 06:00
CRDT- 2017/01/17 06:00
PHST- 2016/09/01 00:00 [received]
PHST- 2016/11/21 00:00 [revised]
PHST- 2016/12/14 00:00 [accepted]
PHST- 2017/01/17 06:00 [pubmed]
PHST- 2017/11/09 06:00 [medline]
PHST- 2017/01/17 06:00 [entrez]
AID - S2152-2650(16)30953-3 [pii]
AID - 10.1016/j.clml.2016.12.001 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):159-164.e2. doi: 
      10.1016/j.clml.2016.12.001. Epub 2016 Dec 26.